In addition to blocking parthanatos, some of the benefit of PARP inhibition is likely derived from attenuation of NF-κB transcription in microglia, astrocytes, and peripheral immune cells, although these anti-inflammatory effects have not been as well-studied in the context of stroke as they have in the context of TBI. The gene discussed is PARP1; the disease is stroke disorder.